Rafferty Asset Management’s CG Oncology CGON Stock Holding History

Rafferty Asset Management’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.57M	Sell	50,263 -17,716	-26%	-$1.16M	0.01%	469
2026 Q1	$4.6M	Sell	67,979 -38,073	-36%	-$2.16M	0.02%	410
2025 Q4	$4.4M	Buy	106,052 +44,368	+72%	+$1.84M	0.02%	461
2025 Q3	$2.48M	Sell	61,684 -18,544	-23%	-$539K	0.01%	595
2025 Q2	$2.09M	Buy	80,228 +8,802	+12%	+$212K	0.01%	599
2025 Q1	$1.75M	Sell	71,426 -7,295	-9%	-$205K	0.01%	610
2024 Q4	$2.26M	Buy	78,721 +126	+0.2%	+$4.31K	0.01%	621
2024 Q3	$2.97M	Buy	78,595 +27,630	+54%	+$969K	0.01%	540
2024 Q2	$1.61M	Buy	+50,965	New	+$1.77M	0.01%	702

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's CGON Position: Q2 2026 in Review

Rafferty Asset Management reduced its CG Oncology (CGON) stake by 26% in Q2 2026, selling an estimated $1.16M and leaving 50,263 shares worth $3.57M. The position accounts for 0.01% of the portfolio, ranked #469.

Rafferty Asset Management first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.6M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Rafferty Asset Management held 50,263 shares of CG Oncology worth $3.57M as of Q2 2026.
Rafferty Asset Management sold 17,716 CG Oncology shares in Q2 2026, an estimated $1.16M.
CG Oncology made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #469 holding.
Rafferty Asset Management first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
Rafferty Asset Management's CG Oncology position peaked at $4.6M in Q1 2026.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.